Haloperidol

May be taken with or without food. May be taken w/ meals to minimise GI irritation.

Severe toxic CNS depression, comatose states, Parkinson's disease, basal ganglia lesions, thyrotoxicosis, significant cardiac disorders (e.g. acute MI, uncompensated heart failure, arrhythmias, clinically significant bradycardia, 2nd or 3rd degree heart block, uncorrected hypokalaemia). Lactation.

Patient with dementia-related psychosis, bipolar disorders, seizures or EEG abnormalities, risk of falls, risk of QT prolongation, risk factors for stroke, severe CV disease, decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, visual problems, and narrow angle glaucoma. Concomitant use with antidepressants and anticholinergic agents. Avoid abrupt withdrawal. Renal and hepatic impairment. Elderly. Children. Pregnancy. Patient Counselling This drug may cause somnolence, if affected, do not drive or operate machinery. Avoid exposure to extreme heat. Avoid strenuous exercise. Ensure adequate fluid intake to prevent dehydration. Monitoring Parameters Monitor mental status, CBC, electrolytes balance, ECG, liver function, serum glucose and HbA_1c level, hemorrhage, abnormal involuntary movements or parkinsonian signs, visual changes.

Significant: Extrapyramidal syndrome (e.g. pseudoparkinsonism, akathisia, tardive dyskinesia, dystonia), CNS depression, anticholinergic effects (e.g. constipation, xerostomia, blurred vision, urinary retention), esophageal dysmotility and aspiration, somnolence, orthostatic hypotension, motor or sensory instability, hyperprolactinaemia. Cardiac disorders: Cardiac arrhythmia, tachycardia. Eye disorders: Visual disturbance. Gastrointestinal disorders: Diarrhoea, nausea, sialorrhoea, vomiting. General disorders and administration site conditions: Injection site reaction. Hepatobiliary disorders: Jaundice. Metabolism and nutrition disorders: Anorexia, hypoglycaemia. Nervous system disorders: Agitation, restlessness, headache. Psychiatric disorders: Confusion, depression, insomnia. Renal and urinary disorders: Urinary retention. Reproductive system and breast disorders: Erectile dysfunction, gynaecomastia, priapism. Respiratory, thoracic and mediastinal disorders: Bronchospasm, dyspnoea. Skin and subcutaneous tissue disorders: Acneiform rash, maculopapular rash. Vascular disorders: Hypotension.
Potentially Fatal: Neuroleptic malignant syndrome, bronchopneumonia, blood dyscrasias (e.g. leucopenia, neutropenia, agranulocytosis), QT prolongation, torsade de pointes.

Altered concentration of haloperidol with CYP3A4 and CYP2D6 inhibitors and inducers. May increase plasma concentration of tricyclic antidepressant.

Antipsychotics

N05AD01 - haloperidol ; Belongs to the class of butyrophenone derivatives antipsychotics.